Evidence map›Paper›PMID 35790062›Full record

SynthesisDermatologic therapy2022

Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis.

Terri Shih, Katrina Lee, Tristan Grogan, Devea R De, Vivian Y Shi, Jennifer L Hsiao

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Cross-Sectional Analysis of Biologic Use in the Treatment of Veterans With Hidradenitis Suppurativa.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Terri ShihDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Katrina LeeDepartment of Dermatology, University of California Los Angeles, Los Angeles, California, USA.
Tristan GroganDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Devea R DeJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Vivian Y ShiDepartment of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0002-7510-9428
Jennifer L HsiaoDepartment of Dermatology, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-8843-3630
University of California, Los Angeles · USJacobs (United States) · USUniversity of Arkansas for Medical Sciences · USUniversity of Southern California · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1TR001881
6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory often recalcitrant to treatment. There is a lack of an updated systematic data review for infliximab use in HS. We conducted a systematic review and meta-analysis of literature on infliximab in HS. This study was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was pre-registered on PROSPERO (CRD42021283596). In 9/2021, MEDLINE and EMBASE were systematically searched for articles on infliximab in HS. Non-English, duplicate, and studies with <5 HS patients were excluded. Study quality was assessed utilizing Cochrane Risk of Bias for prospective trials and Newcastle-Ottawa Scale for cohort studies. Random effects meta-analytical model, Cochran's Q statistic, and I squared index were performed. Nineteen articles (314 patients) met inclusion criteria (six prospective, 13 retrospective studies). All patients with HS severity data available (n = 299) had moderate-to-severe disease. Outcome measures used for meta-analysis of the pooled response rate were largely based on clinician reported outcomes (16 studies). One utilized both clinician and patient assessment. Two utilized patient-reported response alone. The pooled response rate of HS patients to infliximab was 83% (95% CI, 0.71-0.91). The most common adverse events (AEs) included non-serious infections (13.2%) and infusion reaction (2.9%). The rate of serious AEs was 2.9%. Study limitations include the small number of prospective studies and heterogeneity between studies. Overall, infliximab is an effective treatment for moderate-to-severe HS. Efficacy of infliximab in HS should be compared to other biologics in larger, randomized controlled trials.

Indexed as

Hidradenitis SuppurativaAntibodies, MonoclonalHumansInfliximabProspective StudiesRetrospective StudiesAntibodies, MonoclonalInfliximabhidradenitis suppurativainfliximabmeta-analysis

Identifiers

PMID35790062
PMCPMC9539481
OpenAlexW4283818131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.